London
· Delayed Price · Currency is GBP · Price in SEK Orexo AB Company Description
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally.
Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia.
The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder.
The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology.
Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
| Country | Sweden |
| Founded | 1994 |
| Industry | Pharmaceutical Preparations |
| Employees | 116 |
| CEO | Nikolaj Sorensen |
Contact Details
Address: Rapsgatan 7E Uppsala, Uppsala County Uppsala County Sweden | |
| Phone | 46 1 87 80 88 00 |
| Website | orexo.com |
Stock Details
| Ticker Symbol | 0H19 |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nikolaj Sorensen | Chief Executive Officer |
| Fredrik Jarrsten | Chief Financial Officer |
| Cecilia Coupland | Chief Operating Officer |
| Lena Wange | Head of Investor Relations |